声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11月6日,诺和诺德首席财务官Karsten Munk Knudsen表示,该公司了解到,有100人因服用其畅销减肥药和糖尿病药的复方仿制药而住院,10人死亡。目前,诺和诺德已请求美国食品药品监督管理局(FDA)禁止厂商生产Wegovy和Ozempic的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.